Patrick Soon-Shiong discusses lymphopenia dangers with Anktiva benefits

Patrick Soon-Shiong discusses lymphopenia dangers with Anktiva benefits
@DrPatSoonShiong: Soon-Shiong on lymphopenia dangers

Renowned healthcare entrepreneur Patrick Soon-Shiong highlights recent clinical discussions about the dangers of lymphopenia and its impact on survival rates. Reports from Mayo Clinic, Harvard, and the University of Pennsylvania emphasize the critical role of NK and T cell counts in patient survival. Soon-Shiong advocates for the incorporation of Anktiva in combination with these treatments, arguing that it is the path forward for significant change in clinical outcomes. This development underscores a growing recognition of immune cell importance in the clinical community.

These developments around immune response closely follow Soon-Shiong's earlier disclosure of groundbreaking lung cancer trial data, where PDL1 levels were found not to affect NK cells. His ongoing advocacy for innovative approaches also aligns with his past calls for national initiatives to transform cancer care, exemplified when he urged President Trump to advance the Cancer Moonshot.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.